Edwards Lifesciences Corporation

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 05:00:02 24/01/2026 HKT			5-day change	1st Jan Change
83.66 ^USD	-0.92%		-0.82%	-1.87%

01-22	Leerink Partners Adjusts Edwards Lifesciences Price Target to $88 From $87, Maintains Market Perform Rating	MT
01-22	Venus Medtech Clarifies U.S. Patent Lawsuit Involving Subsidiary	MT

RBC Raises Price Target on Edwards Lifesciences to $100 From $95, Keeps Outperform Rating

Published on 12/05/2025 at 08:04 pm HKT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Edwards Lifesciences Corporation

01-22	Leerink Partners Adjusts Edwards Lifesciences Price Target to $88 From $87, Maintains Market Perform Rating	MT
01-22	Venus Medtech Clarifies U.S. Patent Lawsuit Involving Subsidiary	MT
01-20	Piper Sandler Adjusts Price Target on Edwards Lifesciences to $98 From $95, Maintains Overweight Rating	MT
01-20	Stifel Adjusts Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating	MT
01-13	Edwards Lifesciences Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 11:15 AM
01-12	UBS Adjusts Price Target on Edwards Lifesciences to $95 From $92, Maintains Neutral Rating	MT
01-12	Independence, Under Review
01-12	North American Morning Briefing : Stock Futures Fall, Gold Hits Record on Fed Concerns -2-	DJ
01-12	Barclays Adjusts Price Target on Edwards Lifesciences to $104 From $103, Maintains Overweight Rating	MT
01-12	Baird Adjusts Price Target on Edwards Lifesciences to $90 From $87, Maintains Neutral Rating	MT
01-12	RxSight Names Mark Wilterding Finance Chief	MT
01-12	Edwards Lifesciences Drops Bid to Acquire JenaValve Technology	MT
01-11	RxSight, Inc. Appoints Mark Wilterding as Chief Financial Officer, Effective January 11, 2026	CI
01-10	Edwards Lifesciences Drops Merger With JenaValve	DJ
01-10	Edwards says co will not acquire Jenavalve	RE
01-10	US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve	RE
01-09	Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $108 From $104, Maintains Buy Rating	MT
01-09	TD Cowen Upgrades Edwards Lifesciences to Buy From Hold, Adjusts Price Target to $97 From $90	MT
01-06	Evercore ISI Adjusts PT on Edwards Lifesciences to $94 From $92, Maintains Outperform Rating	MT
12-23	Edwards Lifesciences Says FDA Approves Valve Replacement System	MT
12-23	FDA approves Edwards Lifesciences' Sapien M3 mitral valve replacement system as first transseptal transcatheter therapy	RE
12-23	FDA Approves Edwards Lifesciences' Sapien M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy	CI
12-19	North American Morning Briefing : Stock Futures Up as Investors Bet on Fed Rate Cuts -2-	DJ
12-18	Inflation Took a Chill Pill
12-18	JPMorgan Upgrades Edwards Lifesciences to Overweight From Neutral, Adjusts PT to $100 From $90	MT

Chart Edwards Lifesciences Corporation

Duration

Period

EW: Dynamic Chart

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (75.5%); - hemodynamic monitoring systems (6.5%); - other (18%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.9%), Europe (24.3%), Japan (6.3%) and others (10.5%).

Employees

15,800

Sector

Advanced Medical Equipment & Technology

Calendar

02-10 - Q4 2025 Earnings Release

More about the company